Eflornithine
Based on 27 publication(s) in Google Scholar
Eflornithine is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase. Eflornithine is a medication for the treatment of African trypanosomiasis and excessive facial hair growth in women.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.94%
- CAS No.: 70052-12-9
- Formule: C6H12F2N2O2
- Masse moléculaire:182.17
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B1776
SpermidinePolyamine Compound -
HY-B1777
SpermineEndogenous Metabolite -
HY-B0744B
Eflornithine hydrochloride hydrateOrnithine Decarboxylase Inhibitor -
HY-N0455
L-ArginineeNOS Substrate -
HY-B1352
L-OrnithineAmino Acid -
HY-124617A
AMXT-1501 tetrahydrochlorideBacterial Agent And Polyamine Transport System Inhibitor -
HY-10219
RapamycinmTOR Inhibitor -
HY-17026
GemcitabineDNA Synthesis Inhibitor -
HY-108314A
GC7 SulfateDHPS Inhibitor -
HY-W015514
N-(3-Aminopropyl)cyclohexylamineSpermidine Synthase Inhibitor -
HY-B0011
DocetaxelMicrotubule Depolymerization Inhibitor -
HY-17394
CisplatinDNA Alkylator
Publications Citing Use of MedChemExpress (MCE) Eflornithine
More- Nature. 2026 Jul;655(8121):240-250. [Abstract]
- Immunity. 2025 Aug 12;58(8):2019-2034.e11. [Abstract]
- Nat Commun. 2025 Dec 8. [Abstract]
- Nat Commun. 2024 Mar 19;15(1):2461. [Abstract]
- J Clin Invest. 2026 Jun 11.
- Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]
- Sci Adv. 2023 May 19;9(20):eade0718. [Abstract]
- Phytomedicine. 2025 Jun:141:156660. [Abstract]
- Clin Cancer Res. 2025 Nov 20. [Abstract]
- JACC Basic Transl Sci. 2022 Aug 3;7(8):820-840. [Abstract]
- Cell Rep. 2025 Feb 28;44(3):115370. [Abstract]
- Cell Rep. 2025 Jan 28;44(1):115123. [Abstract]
- Food Biosci. 2023 Oct, 55, 102970.
- RSC Adv. 2019 Apr 9;9(20):11026-11037. [Abstract]
- Cancer Nanotechnol. 2023 May 9.
- Commun Biol. 2019 May 8:2:171. [Abstract]
- FASEB J. 2026 Jul 15;40(13):e72108.
- Front Oncol. 2021 Mar 11:11:636373. [Abstract]
- Vet Microbiol. 2026 Jul 31;321:111160.
- J Cardiovasc Transl Res. 2025 Jun;18(3):459-470. [Abstract]
- Biochem Biophys Res Commun. 2026 Feb 12:800:153251. [Abstract]
- Onco Targets Ther. 2020 Nov 17:13:11697-11709. [Abstract]
- Biomed Pharmacother. 2026 Sep:202:119803.
- bioRxiv. 2026 Jul 17.
- The University of Texas at San Antonio. 2025.
- Preprints. 2025 May 22.
- bioRxiv. 2024 Jan 15.
Customer Validation & Images
-
In Vivo Efficacy Study
-
Flow Cytometry
-
RT-PCR
-
Flow Cytometry
-
Histological Imaging/Staining
Voir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
Description
IC50 & Target
|
Trypanosoma |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
>100 μM
Compound: Eflornithine
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay
|
[PMID: 27720295] |
| HepG2 | CC50 |
>100 μM
Compound: Eflornithine
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32292551] |
| HepG2 | CC50 |
>100 μM
Compound: Eflornithine
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32652409] |
| HepG2 | CC50 |
>100 μM
Compound: Eflornithine
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 32795774] |
| L6 | IC50 |
12 μg/mL
Compound: Eflornithine
|
Cytotoxicity against in rat L6 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
Cytotoxicity against in rat L6 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay
|
[PMID: 21353728] |
| MRC5 | IC50 |
>100 μg/mL
Compound: eflornithine
|
Cytotoxicity against human MRC5 cells after 7 days by MTT assay
Cytotoxicity against human MRC5 cells after 7 days by MTT assay
|
[PMID: 19013823] |
| MRC5 | IC50 |
>100 μg/mL
Compound: Eflornithine
|
Cytotoxicity against human MRC5 cells
Cytotoxicity against human MRC5 cells
|
[PMID: 24388808] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 70052-12-9
-
Appearance Solid
-
Masse moléculaire 182.17
-
Formule C6H12F2N2O2
-
Color White to light yellow
-
SMILES
NC(CCCN)(C(F)F)C(O)=O
-
Synonyms
DFMO; MDL71782; RMI71782; α-difluoromethylornithine
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (27)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jul;655(8121):240-250. PMID: 42236947 -
Immunity
Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells. [Abstract]2025 Aug 12;58(8):2019-2034.e11. PMID: 40749666
Eflornithine purchased from MedChemExpress. Usage Cited in: Immunity. 2025 Aug 12;58(8):2019-2034.e11. [Abstract]
Csnk2bTreg−/− and Csnk2bfl/fl mice were inoculated with B16.F10 cells and then orally administered Eflornithine hydrochloride hydrate (1% w/v) in combination with subcutaneous injection of AMXT 1501 around the tumor. We measured tumor growth and analyzed the phenotype of Treg cells in the tumor microenvironment (TME) using multicolor flow cytometry. The combination therapy had no effect on tumor growth in Csnk2bTreg−/− mice but significantly inhibited tumor growth in Csnk2bfl/fl mice.
-
Nat Commun
2025 Dec 8. PMID: 41361241 -
Nat Commun
Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer. [Abstract]2024 Mar 19;15(1):2461. PMID: 38504107 -
-
Adv Sci (Weinh)
Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer. [Abstract]2025 Nov 21:e12508. PMID: 41271556
Eflornithine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]
Bar graphs showing the proportion of ALDH+ cells in OVCAR3, OVCAR8, and SKOV3 treated with THP-1-derived Mφ+ACs CM, THP-1-derived Mφ+ACs treated with 1 mM Eflornithine CM, respectively, for 48 h were presented.
Eflornithine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]
Bar graph showing the relative mRNA expression of SOX2, ALDH1A1, and ALDH1A3 in OVCAR3 treated with THP-1 derived Mφ +ACs CM, THP-1 derived Mφ+ACs treated with 1 mM Eflornithine CM separately for 48 h.
-
Sci Adv
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation. [Abstract]2023 May 19;9(20):eade0718. PMID: 37205755
Eflornithine purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 May 19;9(20):eade0718. [Abstract]
Percentage of IFN-γ+ and mean fluorescence intensity (MFI) of Ki-67 in CD8+ T cells after anti-CD3 antibody stimulation versus anti-CD3 antibody plus rSema4A stimulation with or without Sardomozide Dihydrochloride (10 μM) and Eflornithine hydrochloride hydrate (500 μM).
-
Phytomedicine
Oleic acid regulates CD4+ T cells differentiation by targeting ODC1-mediated STAT5A phosphorylation in Vogt-Koyanagi-Harada disease. [Abstract]2025 Jun:141:156660. PMID: 40203473 -
Clin Cancer Res
Spermidine Secreted by Apoptotic Cells Enhances Chemotherapy Resistance by Modulating β-Catenin Activity in Osteosarcoma. [Abstract]2025 Nov 20. PMID: 41263700 -
JACC Basic Transl Sci
Targeting Myocardial Mitochondria-STING-Polyamine Axis Prevents Cardiac Hypertrophy in Chronic Kidney Disease. [Abstract]2022 Aug 3;7(8):820-840. PMID: 36061341 -
Cell Rep
Intestinal microbiota affects the progression of colorectal cancer by participating in the host intestinal arginine catabolism. [Abstract]2025 Feb 28;44(3):115370. PMID: 40022728 -
Cell Rep
2025 Jan 28;44(1):115123. PMID: 39932195 -
-
RSC Adv
Spermine modified polymeric micelles with pH-sensitive drug release for targeted and enhanced antitumor therapy. [Abstract]2019 Apr 9;9(20):11026-11037. PMID: 35520220 -
-
Commun Biol
2019 May 8:2:171. PMID: 31098404
Eflornithine purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]
Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. Immunostaining of IDO1 in the ileum after L-Orn administration in wt mice or after L-Orn inhibitor DFMO administration in human REG3Atg mice was performed.
Eflornithine purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]
Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. HPLC/MASS of L-Kyn in the ileum epithelial cells after administration of L-Orn or L-Orn inhibitor DFMO.
Eflornithine purchased from MedChemExpress. Usage Cited in: Commun Biol. 2019 May 8:2:171. [Abstract]
Eflornithine (DFMO) was administered as a 1% solution in drinking distilled H₂O to mice for 14 days. The mean DFMO consumption of mice was ∼1.5 g/kg/d. Flow cytometry of RORγt (+) IL-22(+) cells in the ileum of mice after administering L-Orn or L-Orn inhibitor DFMO.
-
-
Front Oncol
Dual Inhibition of Ornithine Decarboxylase and A1 Adenosine Receptor Efficiently Suppresses Breast Tumor Cells. [Abstract]2021 Mar 11:11:636373. PMID: 33777791 -
-
J Cardiovasc Transl Res
LACC1 Enhances Polyamine Immunometabolism in Inflammatory Macrophages to Inhibit Atherosclerosis Progression. [Abstract]2025 Jun;18(3):459-470. PMID: 40293654 -
Biochem Biophys Res Commun
Alpha-difluoromethylornithine suppresses angiogenesis via the FLI1-CLEC14A-VEGFC pathway in retinal endothelial cells. [Abstract]2026 Feb 12:800:153251. PMID: 41548484 -
Onco Targets Ther
Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects Against Hepatocellular Carcinoma Cells. [Abstract]2020 Nov 17:13:11697-11709. PMID: 33244237 -
-
-
-
-
Solvant et solubilité
In Vitro:
H2O : 83.33 mg/mL (457.43 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Burri C, et al. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003 Jun;90 Supp 1:S49-52. [Content Brief]
[2]. Balfour JA, et al. Topical eflornithine. Am J Clin Dermatol. 2001;2(3):197-201; discussion 202. [Content Brief]
[3]. Kumar A, et al. A method to improve the efficacy of topical eflornithine hydrochloride cream. Drug Deliv. 2016 Jun;23(5):1495-501. [Content Brief]
[4]. Lipke DW, et al. Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. Clin Exp Hypertens. 1997 Apr;19(3):297-312. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 5.4894 mL | 27.4469 mL | 54.8938 mL | 137.2345 mL |
| 5 mM | 1.0979 mL | 5.4894 mL | 10.9788 mL | 27.4469 mL | |
| 10 mM | 0.5489 mL | 2.7447 mL | 5.4894 mL | 13.7234 mL | |
| 15 mM | 0.3660 mL | 1.8298 mL | 3.6596 mL | 9.1490 mL | |
| 20 mM | 0.2745 mL | 1.3723 mL | 2.7447 mL | 6.8617 mL | |
| 25 mM | 0.2196 mL | 1.0979 mL | 2.1958 mL | 5.4894 mL | |
| 30 mM | 0.1830 mL | 0.9149 mL | 1.8298 mL | 4.5745 mL | |
| 40 mM | 0.1372 mL | 0.6862 mL | 1.3723 mL | 3.4309 mL | |
| 50 mM | 0.1098 mL | 0.5489 mL | 1.0979 mL | 2.7447 mL | |
| 60 mM | 0.0915 mL | 0.4574 mL | 0.9149 mL | 2.2872 mL | |
| 80 mM | 0.0686 mL | 0.3431 mL | 0.6862 mL | 1.7154 mL | |
| 100 mM | 0.0549 mL | 0.2745 mL | 0.5489 mL | 1.3723 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Eflornithine Related Classifications
HY-B0744 Related Classifications
Powered by Bioz